The final HRSA manufacturer 340B program audit conducted in fiscal year 2023 had no adverse findings for Teva Pharmaceuticals.

Teva Ends 340B Contract Pharmacy Restrictions in Arkansas in Response to State Law

Teva Pharmaceuticals this week ended its 340B contract pharmacy restrictions in Arkansas in response to a state law that prevents [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at